Physician PracticeResearch Use OnlyWADA Prohibited

Reta

Investigational triple GIP/GLP-1/GCG receptor agonist. Phase II data shows up to 24% mean weight loss at 48 weeks — among the highest reported for any metabolic compound to date.

MetabolicTriple AgonistGIP/GLP-1/GCGInjectablePhase III
QUICK FACTS
CLASSTriple GIP/GLP-1/GCG receptor agonist
MECHANISMActivates GIP, GLP-1, and GCG receptors
PHASEPhase II completed; Phase III initiated
PHASE II DATA24% mean weight loss at 48 weeks
EVIDENCE STATUSInvestigational — trial protocols are evidence benchmark
WADA STATUSProhibited
Overview

Reta is an investigational triple receptor agonist developed by Eli Lilly that activates GIP, GLP-1, and GCG receptors simultaneously. The addition of GCG receptor agonism to the dual incretin mechanism of tirze is proposed to enhance energy expenditure through thermogenic effects, potentially explaining the superior weight loss data observed in Phase II trials.

A Phase II clinical trial reported 24% mean weight loss at 48 weeks with the highest dose tested — outcomes that exceed those of any currently approved metabolic agent and rival bariatric surgery results in some analyses. Phase III trials are underway to confirm efficacy and safety for an obesity indication.

Physician-practice off-label use exists but extrapolates significantly from Phase II data. The compound is not approved for any indication, and the optimal off-trial protocol remains undefined. Joseph describes 0.5–2 mg weekly as a starting range in practice contexts.

Research Areas
Metabolic researchObesity pharmacologyTriple receptor agonismGCG pathway researchEnergy expenditure researchCardiovascular metabolic research
Available Evidence3 categories
Human (Phase II)Phase II trial: 24% mean weight loss at 48 weeks. Statistically significant vs placebo. Among the highest reported outcomes for any metabolic compound to date.
MechanisticGCG receptor activation adds thermogenic/energy expenditure dimension to dual GIP/GLP-1 mechanism — proposed mechanism for enhanced efficacy vs dual agonists like tirze.
UncertainLong-term safety, optimal dosing for non-trial contexts, and off-label protocols not established. Phase III confirmatory data pending.
Documented Research Benefits6 documented
Weight reduction
Phase II — up to 24%
GLP-1 receptor effects
human
GIP receptor effects
human
GCG receptor effects
human
Metabolic marker improvement
Phase II
Energy expenditure increase
proposed mechanism
Research Pairings3 common
Cagrilintide
Amylin analog sometimes discussed alongside GLP-class agents. Cumulative GI burden is a key consideration.
View Cagrilintide →
MOTS-c
Mitochondrial support in metabolic protocols — physician practice based complementary approach.
View MOTS-c →
Tessa
GH axis concurrent discussion in physician practice. Not a standard combination.
View Tessa →

What are you researching?

Tell us your focus area and we’ll send a personalized research guide.

Safety & Regulatory Status

Reta is not FDA-approved for any indication. GI side effect profile similar to GLP-1 class — nausea, vomiting, diarrhea. The GCG component adds potential cardiovascular considerations. Research use only. WADA-prohibited. All information for educational reference only.

Get the Research Guide

Research summaries, evidence tiers, and COA-verified sourcing. Published by Forge Scientific. No spam.